世界の嚢胞性線維症（CF症）治療薬市場（2018年～2022年）

嚢胞性線維症（CF症）治療薬について

嚢胞性線維症（CF症）は、主に肺、時として肝臓、膵臓、腸および腎臓にも影響を及ぼす遺伝性疾患の一種で、常染色体劣性遺伝を示すことで知られています。塩素イオンチャネル（CFTR）の遺伝子変異によって引き起こされます。

Technavioのアナリストは、2018年から～2022年の期間に、世界の嚢胞性線維症（CF症）治療薬市場が17.28％のCAGRで成長すると予測しています。

当レポートでは、嚢胞性線維症（CF症）治療薬の世界市場を調査し、市場の概要、・地域別の市場動向、市場規模の推移と予測、成長促進要因ならびに課題の分析、競合情勢、主要企業のプロファイルなど包括的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 調査範囲

第3章 調査方法

第4章 イントロダクション

• 市場概要

第5章 市場状況

• 市場のライフサイクル
• 市場特性
• 市場セグメンテーション分析

第6章 市場規模

• 市場の定義
• 市場規模
• 市場規模と予測

第7章 ファイブフォース分析

• 買い手の交渉力
• 供給企業の交渉力
• 新規参入業者の脅威
• 代替品の脅威
• 競争企業間の敵対関係
• 市場状況

第8章 市場セグメンテーション：薬品クラス別

• 比較：薬品クラス別
• CFTRモジュレーター
• 粘液溶解薬
• 膵酵素補充薬（PERT）
• 抗感染薬
• 気管支拡張薬
• 市場機会：薬品クラス別

第9章 顧客情勢

第10章 地域情勢

• 地域比較
• 南北アメリカ
• 欧州・中東・アフリカ地域
• アジア太平洋地域
• 市場機会

第11章 意思決定の枠組み

第12章 成長要因と課題

• 市場の成長要因
• 市場の課題

第13章 市場動向

• 戦略的コラボレーション
• 医薬品の開発と供給のための技術進歩

第14章 ベンダー情勢

• 概要
• 創造的破壊
• 競合シナリオ

第15章 ベンダー分析

• 対象ベンダー
• ベンダーの分類
• ベンダーの市場ポジショニング
• AbbVie
• Gilead
• F. Hoffmann-La Roche
• Vertex Pharmaceuticals

第16章 付録

• 略語のリスト

• Exhibit 01: Autosomal recessive pattern of inheritance in CF
• Exhibit 02: Effects of CF on different body parts
• Exhibit 03: Most common CFTR mutations
• Exhibit 04: Global birth prevalence of CF by 2017
• Exhibit 05: Diagnosis and treatment of CF
• Exhibit 06: Parent market
• Exhibit 07: Market characteristics
• Exhibit 08: Market segments
• Exhibit 09: Market definition: Inclusions and exclusions checklist
• Exhibit 10: Market size
• Exhibit 11: Validation techniques employed for market sizing 2017
• Exhibit 12: Global CF therapeutics market 2017-2022 ($ millions)
• Exhibit 13: Global CF therapeutics market: Year over year growth 2018-2022 (%)
• Exhibit 14: Five forces analysis 2017
• Exhibit 15: Five forces analysis 2022
• Exhibit 16: Bargaining power of buyers
• Exhibit 17: Bargaining power of suppliers
• Exhibit 18: Threat of new entrants
• Exhibit 19: Threat of substitutes
• Exhibit 20: Threat of rivalry
• Exhibit 21: Market condition: Five forces 2017
• Exhibit 22: Global CF therapeutics market by drug class 2017-2022 (% share)
• Exhibit 23: Comparison by drug class
• Exhibit 24: Global CF therapeutics market by CFTR modulators 2017-2022 ($ millions)
• Exhibit 25: KALYDECO description
• Exhibit 26: ORKAMBI description
• Exhibit 27: Global CF therapeutics market by CFTR modulators: Year over year growth 2018-2022 (%)
• Exhibit 28: Global CF therapeutics market by mucolytics 2017-2022 ($ millions)
• Exhibit 29: Global CF therapeutics market by mucolytics: Year over year growth 2018-2022 (%)
• Exhibit 30: Global CF therapeutics market by PERT 2017-2022 ($ millions)
• Exhibit 31: Global CF therapeutics market by PERT: Year over year growth 2018-2022 (%)
• Exhibit 32: Global CF therapeutics market by anti-infectives 2017-2022 ($ millions)
• Exhibit 33: Global CF therapeutics market by anti-infectives: Year over year growth 2018-2022 (%)
• Exhibit 34: Global CF therapeutics market by bronchodilators 2017-2022 ($ millions)
• Exhibit 35: Global CF therapeutics market by bronchodilators: Year over year growth 2018-2022 (%)
• Exhibit 36: Market opportunity by drug class
• Exhibit 37: Customer landscape
• Exhibit 38: Global CF therapeutics market by region 2017-2022 (% share)
• Exhibit 39: Regional comparison
• Exhibit 40: CF therapeutics market in Americas 2017-2022 ($ millions)
• Exhibit 41: CF therapeutics market in Americas: Year over year growth 2018-2022 (%)
• Exhibit 42: Top three countries in Americas
• Exhibit 43: CF therapeutics market in EMEA 2017-2022 ($ millions)
• Exhibit 44: CF therapeutics market in EMEA: Year over year growth 2018-2022 (%)
• Exhibit 45: Top three countries in EMEA
• Exhibit 46: CF therapeutics market in APAC 2017-2022 ($ millions)
• Exhibit 47: CF therapeutics market in APAC: Year over year growth 2018-2022 (%)
• Exhibit 48: Top three countries in APAC
• Exhibit 49: Market opportunity
• Exhibit 50: Few drugs with breakthrough therapy designation for CF
• Exhibit 51: Few drugs with Orphan Drug Designation for CF
• Exhibit 52: Few CF therapeutics discontinued from development
• Exhibit 53: Partnerships and collaborations between companies for development of CF therapeutics
• Exhibit 54: Vendor landscape
• Exhibit 55: Landscape disruption
• Exhibit 56: Competitive structure analysis of global CF therapeutics market 2017
• Exhibit 57: Vendors covered
• Exhibit 58: Vendor classification
• Exhibit 59: Market positioning of vendors
• Exhibit 60: AbbVie: Overview
• Exhibit 61: AbbVie: Business segments
• Exhibit 62: AbbVie: Organizational developments
• Exhibit 63: AbbVie: Geographic focus
• Exhibit 64: AbbVie: Segment focus
• Exhibit 65: AbbVie: Key offerings
• Exhibit 66: AbbVie: Key customers
• Exhibit 67: Gilead: Overview
• Exhibit 68: Gilead: Business segments
• Exhibit 69: Gilead: Organizational developments
• Exhibit 70: Gilead: Geographic focus
• Exhibit 71: Gilead: Segment focus
• Exhibit 72: Gilead: Key offerings
• Exhibit 73: Gilead: Key customers
• Exhibit 74: F. Hoffmann-La Roche: Overview
• Exhibit 75: F. Hoffmann-La Roche: Business segments
• Exhibit 76: F. Hoffmann-La Roche: Organizational developments
• Exhibit 77: F. Hoffmann-La Roche: Geographic focus
• Exhibit 78: F. Hoffmann-La Roche: Segment focus
• Exhibit 79: F. Hoffmann-La Roche: Key offerings
• Exhibit 80: F. Hoffmann-La Roche: Key customers
• Exhibit 81: Vertex Pharmaceuticals: Overview
• Exhibit 82: Vertex Pharmaceuticals: Business segments
• Exhibit 83: Vertex Pharmaceuticals: Organizational developments
• Exhibit 84: Vertex Pharmaceuticals: Geographic focus
• Exhibit 85: Vertex Pharmaceuticals: Segment focus
• Exhibit 86: Vertex Pharmaceuticals: Key offerings
• Exhibit 87: Vertex Pharmaceuticals: Key customers

About Cystic Fibrosis Therapeutics

CF is a genetic disorder that mostly affects the lungs and sometimes other parts of the body such as the liver, pancreas, intestines, and the kidneys. The disease is inherited in an autosomal recessive manner. It is due to mutations caused in both the copies of the gene for the CFTR protein.

Technavio's analysts forecast the global cystic fibrosis therapeutics market to grow at a CAGR of 17.28% during the period 2018-2022.

Covered in this report

The report covers the present scenario and the growth prospects of the global cystic fibrosis therapeutics market for 2018-2022. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:

• Americas
• APAC
• EMEA

Technavio's report, Global Cystic Fibrosis Therapeutics Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

• AbbVie
• Gilead
• F. Hoffmann-La Roche
• Vertex Pharmaceuticals

Market driver

• Improved diagnostic technologies
• For a full, detailed list, view our report

Market challenge

• Drug discontinuation
• For a full, detailed list, view our report

Market trend

• Strategic collaborations
• For a full, detailed list, view our report

Key questions answered in this report

• What will the market size be in 2022 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION

• Market outline

PART 05: MARKET LANDSCAPE

• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 06: MARKET SIZING

• Market definition
• Market sizing
• Market size and forecast

PART 07: FIVE FORCES ANALYSIS

• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

PART 08: MARKET SEGMENTATION BY DRUG CLASS

• Comparison by drug class
• CFTR modulators
• Mucolytics
• PERT
• Anti-infectives
• Bronchodilators
• Market opportunity by drug class

PART 09: CUSTOMER LANDSCAPE

PART 10: REGIONAL LANDSCAPE

• Regional comparison
• CF therapeutics market in Americas
• CF therapeutics market in EMEA
• CF therapeutics market in APAC
• Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

• Market Drivers
• Market challenges

PART 13: MARKET TRENDS

• Strategic collaborations
• Advances in technology for drug development and delivery

PART 14: VENDOR LANDSCAPE

• Overview
• Landscape disruption
• Competitive scenario

PART 15: VENDOR ANALYSIS

• Vendors covered
• Vendor classification
• Market positioning of vendors
• AbbVie
• Gilead
• F. Hoffmann-La Roche
• Vertex Pharmaceuticals

PART 16: APPENDIX

• List of abbreviations